Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1

Journal of Medicinal Chemistry

Volumn 47, Issue 24, 2004, Pages 5912-5922

  Hopkins, Andrew L ^a,e   Ren, Jingshan ^a   Milton, John ^c   Hazen, Richard J ^d   Chan, Joseph H ^d   Stuart, David I ^a   Stammers, David K ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 CYCLOHEXYLOXY 3 ISOPROPYLQUINOL 2 ONE; 6 CHLORO 4 CYCLOHEXYLOXY 3 PROPYL 1H QUINOL 2 ONE; 6 CHLORO 4 CYCLOHEXYLSULFINYL 3 PROPYL 1H QUINOL 2 ONE; 6 CHLORO 4 CYCLOHEXYLTHIO 3 PROPYL 1H QUINOL 2 ONE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; GENETIC RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; VIRUS MUTATION;

ANTI-HIV AGENTS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; QUINOLONES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8744243260     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040071z     Document Type: Article

References (67)

1. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; et al. Highly specific inhibition of human immunodeficiency virus type-1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375-1381.
2. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; et al. A novel lead for specific anti-HIV-1 agents: 1-[2-hydroxyethoxymethyl]-6- phenylthiothymine. J. Med. Chem. 1989, 32, 2507-2509.
3. Pauwels, R.; Andries, K.; Desmytes, J.; Schols, D.; Kukla, M. J.; et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343.
4. Debyser, Z.; Pauwels, R.; Andries, K.; Desmytes, J.; Kukla, M.; et al. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1451-1455.
5. Balzarini, J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem. 2004, 4, 921-944.
6. Ren, J. S.; Esnouf, R. M.; Garman, E.; Somers, D.; Ross, C.; et al. High-resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
7. Esnouf, R.; Ren, J. S.; Ross, C.; Jones, Y.; Stammers, D.; et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
8. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; et al. Complexes of HIV-1 reverse transcriptase with Inhibitions of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
9. Esnouf, R. M.; Ren, J.; Hopkins, A. L.; Ross, C. K.; Jones, E. Y.; et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and bis(heteroaryl)piperazine (BHAP) U-90152. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 3984-3989.
10. Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; et al. non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present and future perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
11. De Clercq, E. Perspectives for non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco 1999, 54, 26-45.
12. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors. (NNRTI) in the therapy of HIV-1 infections. Antiviral Res. 1998, 38, 153-179.
13. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373, 123-126.
14. Perelson, A. S.; Neumann, A. U.; Markowitz, M.; Leonard, J. M.; Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 1996, 271, 1582-1586.
15. Wei, X.; Ghosh, S. K.; Taylor, M. E.; Johnson, V. A.; Emini, E. A.; et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373, 117-112.
16. Nájera, I.; Holguín, A.; Quiñones-Mateu, M. E.; Muñoz-Fernández, A.; Nájera, R.; et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 1995, 69, 23-31.
17. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Conway, B.; D'Aquila, R. T.; et al. Drug resistance mutations in HIV-1. Top. HIV Med. 2003, 11, 215-221.
18. Bangsberg, D. R.; M. A.; Deeks, S. G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 2004, 53, 696-699.
19. Domaoal, R. A.; Demeter, L. M. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int. J. Biochem. Cell Biol. 2004, 36, 1735-1751.
20. Schinazi, R. F.; Larder, B. A.; Mellors, J. W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 1997, 6.
21. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. J.; Moereels, H.; et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 1996, 264, 1085-1100.
22. Hsiou, Y.; Das, K.; Ding, J.; Clark, A. J.; Kleim, J.; et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 1998, 284, 313-323.
23. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 2001, 312, 795-805.
24. Spence, R. A.; Anderson, K. S.; Johnson, K. A. HIV-1 reverse transciptase resistance to non-nucleoside inhibitors. Biochemistry 1996, 35, 1054-1063.
25. Maga, G.; Amecker, M.; Ruel, N.; Hübscher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamics or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274, 738-747.
26. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. J.; Boyer, P.; et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 2001, 309, 437-445.
27. Kleim, J.-P.; Bender, R.; Billhardt, U.-M.; Meichsner, C.; Riess, G.; et al. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 1993, 37, 1659-1664.
28. Kleim, J.-P.; Bender, R.; Kirsch, R. Preclinical evaluation of HBY 097, a novel non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 1995, 39, 2253-2257.
29. Jacobo-Molina, A.; Ding, J.; Nanni, R. G.; Clark, A. D., Jr.; Lu, X.; et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320-6324.
30. Yu, Q.; Ottmann, M.; Pechoux, C.; Le Grice, S.; Darlix, J.-L. Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation. J. Virol. 1998, 72, 7676-7680.
31. Ghosh, M.; Jacques, P. S.; Rodgers, D. W.; Ottmann, M.; Darlix, J.-L.; et al. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry 1996, 35, 8553-8562.
32. Jacques, P. S.; Wöhrl, B. M.; Ottmann, M.; Darlix, J.-L.; Le Grice, S. Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in the template-primer utilization. J. Biol. Chem. 1994, 269, 26472-26478.
33. Powell, M. D.; Ghosh, M.; Jacques, P. S.; Howard, K. J.; Le Grice, S.; et al. Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase results in selective loss of RNA priming activity. J. Biol. Chem. 1997, 272, 13262-13269.
34. Palaniappan, C.; Wisniewski, M.; Jacques, P. S.; Le Grice, S.; Fay, P. J.; et al. Mutations within the primer grip of HIV-1 reverse transcriptase results in a loss of RNaseH function. J. Biol. Chem. 1997, 272, 11157-11164.
35. Pelemans, H.; Esnouf, R. M.; Parniak, M. A.; Vandamme, A.-M.; De Clercq, E.; et al. A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. J. Gen. Virol. 1998, 79, 1347-1352.
36. Fujiwara, T.; Sato, A.; el-Farrash, M.; Miki, S.; Abe, K.; et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 46, 1340-1345.
37. Balzarini, J.; Pelemans, H.; Esnouf, R.; De Clercq, E. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res. Hum. Retroviruses 1998, 14, 255-260.
38. Pelemans, H.; Esnouf, R.; Dunkler, A.; Parniak, M. A.; Vandamme, A. M.; et al. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 1997, 71, 8195-8203.
39. Kleim, J.-P.; Winkler, I.; Rosner, M.; Kirsch, R.; Rubsamen-Waigmann, H.; et al. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 1997, 237, 112-118.
40. Bacheler, L. T.; Anton, E. D.; Kudish, P.; Baker, D.; Bunville, J.; et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 2000, 44, 2475-2484.
41. Ghosh, M.; Williams, J.; Powell, M. D.; Levin, J., G.; Le Grice, S. F. Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization. Biochemistry 1997, 36, 5758-5768.
42. Wöhrl, B. M.; Krebs, R.; Thrall, S. H.; Le Grice, S. F.; Scheidig, A. J.; et al. Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66. Implications for DNA synthesis and dimerization. J. Biol. Chem. 1997, 272, 17581-17587.
43. Hopkins, A. L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; et al. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J. Med. Chem. 1999, 42, 4500-4505.
44. Pelemans, H.; Esnouf, R.; De Clercq, E.; Balzarini, J. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol. Pharmacol. 2000, 57, 954-960.
45. Harrigan, P.; Salim, M.; Stammers, D.; Wynhoven, B.; Brumme, Z.; et al. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J. Virol. 2002, 76, 6836-6840.
46. Pelemans, H.; Esnouf, R. M.; Jonckheere, H.; De Clercq, E.; Balzarini, J. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J. Biol. Chem. 1988, 273, 34234-34239.
47. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
48. Tanaka, H.; Walker, R. T.; Hopkins, A. L.; Ren, J.; Jones, E. Y.; et al. Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an omega-functionalized acyclic structure. Antivir. Chem. Chemother. 1998, 9, 352-332.
49. Ren, J.; Nichols, C.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 2000, 275, 14316-14320.
50. 13C NMR spectral studies. J. Chem. Soc., Perkins Trans. 1 1993, 22, 2747-2755.
51. Hunter, C. A.; Sander, J. K. M. The nature of π-π interactions. J. Am. Chem. Soc. 1990, 112, 5525-5534.
52. Freeman, G. A.; Andrews, C. A., III; Hopkins, A. L.; Lowell, G. S.; Gonzales, S. S.; et al. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. 2003, in press.
53. Goodford, P. J. A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 829-857.
54. Powell, M. J. D. Restart procedures for the conjugate gradient method. Math. Program. 1977, 12, 241-254.
55. Brünger, A. T. X-PLOR; Yale University: New Haven.
56. Daresbury Laboratory, D., Warrington, U.K. Chemical Database Service, CLRC.
57. Tramontano, E.; Cheng, Y.-C. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem. Pharmacol. 1992, 43, 1371-1376.
58. Spira, T. J.; Bozeman, L. H.; Holman, R. C.; Warfield, D. T.; Phillips, S. K.; et al. Micromethod for assaying reverse transcriptase of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J. Clin. Microbiol. 1987, 25, 97-99.
59. Averett, D. R. Anti-HIV compounds assessment by two high capacity assays. J. Virol. Methods 1989, 23, 263-276.
60. Schwartz, O. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res. Hum. Retroviruses 1988, 4, 441-447.
61. Daluge, S. M.; Purifoy, D. J. M.; Savina, P. M.; St. Clair, M. H.; Parry, N. P.; et al. 5-Chloro2′3′-dideoxy-3′-fluorouridine 935U83, a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 1994, 38, 1590-1603.
62. Dornsife, R. E. Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with the additive inhibition of normal human marrow progenitor cells. Antimicrob. Agents Chemother. 1991, 35, 322-328.
63. Stammers, D. K.; Somers, D. O. N.; Ross, C. K.; Kirby, I.; Ray, P. H.; et al. Crystals of HIV-1 reverse transciptase diffracting to 2.2 A resolution. J. Mol. Biol. 1994, 242, 586-588.
64. Otwinowski, Z. Oscillation data reduction program. Data Collection and Processing; SERC Daresbury Laboratory: Warrington, England, 1993; pp 56-62.
65. Brunger, A.; Adams, P.; Clore, G.; DeLano, W.; Gros, P.; et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 1998, 54, 905-921.
66. Engh, R. A.; Huber, R. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr. 1991, A47, 392-400.
67. Jones, T. A. Interactive computer graphics: FRODO. Methods Enzymol. 1985, 115, 157-171.